Effect of dose reductions on response to 500-μg darbepoetin alfa administered once every 3 weeks for the treatment of chemotherapy-induced anemia:: Analysis from a randomized, double-blind, active-controlled trial

被引：0
|
作者：
Canon, JL
Vansteenkiste, J
Bodoky, G
Mateos, MV
Bastit, L
Ferreira, I
Lillie, T
机构：
[1] Ctr Hosp Notre Dame & Reine Fabiola, Charleroi, Belgium
[2] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[3] Szt Laszlo Hosp, Budapest, Hungary
[4] Univ Salamanca, Hosp Clin, E-37008 Salamanca, Spain
[5] Ctr Frederic Joliot, Rouen, France
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.3558.3558
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3558
引用
收藏
页码：993A / 993A
页数：1
相关论文
共 42 条
  • [1] Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia
    Canon, JL
    Vansteenkiste, J
    Bodoky, G
    Mateos, MV
    Bastit, L
    Ferreira, J
    Rossi, G
    Amado, RG
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (04): : 273 - 284
  • [2] Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia
    Taylor, K
    Ganly, P
    Charu, V
    DiBenedetto, J
    Kracht, K
    Rossi, G
    Hernandez, E
    BLOOD, 2005, 106 (11) : 992A - 993A
  • [3] Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy.
    Canon, JL
    Vansteenkiste, J
    Bodoky, G
    Mateos, MV
    Bastit, L
    Ferreira, I
    Rossi, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1098S - 1098S
  • [4] Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia
    Hernandez, Enrique
    Ganly, Peter
    Charu, Veena
    DiBenedetto, Joseph
    Tomita, Dianne
    Lillie, Tom
    Taylor, Kerry
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (09) : 2109 - 2120
  • [5] Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
    Auerbach, Michael
    Silberstein, Peter T.
    Webb, R. Timothy
    Averyanova, Svetlana
    Ciuleanu, Tudor-Eliade
    Shao, James
    Bridges, Kenneth
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (09) : 655 - 663
  • [6] Darbepoetin alfa administered once every 3 weeks (Q3W) is effective for treating anaemia in patients receiving multicycle chemotherapy: results of a randomised, double-blind, active-controlled trial
    Canon, J.
    Vansteenkiste, J.
    Bodoky, G.
    Mateos, M. V.
    Bastit, L.
    Ferreira, I.
    Amado, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 370 - 370
  • [7] Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Michael Hedenus
    Pere Gascon
    Carsten Bokemeyer
    Heinz Ludwig
    Jan Vermorken
    Lisa Hamilton
    Ken Bridges
    Beatriz Pujol
    BMC Cancer, 9
  • [8] Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
    Bastit, Laurent
    Vandebroek, An
    Altintas, Sevilay
    Gaede, Bernd
    Pinter, Tamas
    Suto, Tamas S.
    Mossman, Tony W.
    Smith, Kay E.
    Vansteenkiste, Johan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1611 - 1618
  • [9] Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level &lt; 10 g/dL versus ≥ 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled
    Vansteenkiste, Johan
    Hedenus, Michael
    Gascon, Pere
    Bokemeyer, Carsten
    Ludwig, Heinz
    Vermorken, Jan
    Hamilton, Lisa
    Bridges, Ken
    Pujol, Beatriz
    BMC CANCER, 2009, 9 : 311
  • [10] Darbepoetin alfa for the treatment of chemotherapy-induced anemia: Disease progression and survival analysis from four randomized double-blind placebo-controlled trails
    Hedenus, M
    Vansteenkiste, J
    Kotasek, P
    Austin, M
    Amado, RG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6941 - 6948
12345